// App-Quantinova.ai

160 : Use of Rituximab Compared to Anti-TNF Agents as Second and Third Line Therapy in Patients with Rheumatoid Arthritis. A 6 Year Follow-Up Report from the Rhumadata Clinical Database and Registry

Researchers

Presenter

  • Denis Choquette

Principal Investigators

  • N/A

Medical Centers

  • Institut de Rhumatologie, Montreal, QC, Canada

  • Institut de Rhumatologie, Montreal, QC, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

Biomarkers

  • Estrogen receptor alpha

  • Interferon

Drug/Treatment

  • Adalimumab

  • Infliximab

  • Etanercept

  • CHS-0214

  • Rituximab

Outcome

  • Unknown

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved